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Abstract
Encapsulated-cell therapy (ECT) is an attractive approach for continuously delivering
freshly synthesized therapeutics to treat sight-threatening posterior eye diseases, circum-
venting repeated invasive intravitreal injections and improving local drug availability clini-
cally. Composite collagen-alginate (CAC) scaffold contains an interpenetrating network that
integrates the physical and biological merits of its constituents, including biocompatibility,
mild gelling properties and availability. However, CAC ECT properties and performance in
the eye are not well-understood. Previously, we reported a cultured 3D CAC system that
supported the growth of GDNF-secreting HEK293 cells with sustainable GDNF delivery.
Here, the system was further developed into an intravitreally injectable gel with 1x104 or
2x105 cells encapsulated in 2mg/ml type I collagen and 1% alginate. Gels with lower algi-
nate concentration yielded higher initial cell viability but faster spheroid formation while
increasing initial cell density encouraged cell growth. Continuous GDNF delivery was
detected in culture and in healthy rat eyes for at least 14 days. The gels were well-tolerated
with no host tissue attachment and contained living cell colonies. Most importantly, gel-
implanted in dystrophic Royal College of Surgeons rat eyes for 28 days retained photore-
ceptors while those containing higher initial cell number yielded better photoreceptor sur-
vival. CAC ECT gels offers flexible system design and is a potential treatment option for
posterior eye diseases.
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Introduction
It is estimated that 285 million people are visually impaired or blind around the world [1]. Lim-
ited treatment options are yet available for common sight-threatening diseases such as degen-
erative retinopathies, diabetic retinopathies, glaucoma, cytomegalovirus (CMV) retinitis,
uveitis, and retinal vein and artery occlusions due to the lack of effective drug delivery system
[2]. Although repeated administrations of therapeutics through the invasive intravitreal route
are clinically performed to improve local drug availability, this type of drug administration is
plagued by heavy treatment burden on physicians and patients as well as cumulative risks and
potential complications such as infectious endophthalmitis, elevated intraocular pressure, reti-
nal vascular occlusion and rhegmatogenous retinal detachment [3]. Effective sustainable drug
delivery platforms are warranted.
Encapsulated-cell therapy (ECT) is an attractive approach for delivering freshly synthesized
therapeutics targeting a wide range of vision-threatening diseases in the posterior eye [4]. Since
the pioneering work by Chang et al., ECT has been evolved into a new area of biomedical
research and applied to a plethora of diseases and targeted locations [5]. By encapsulating and
immunoisolating drug-secreting cells of autogeneic, allogeneic and xenogeneic sources in a
semipermeable membrane and/or matrix, neuroactive agents can be continuously delivered at
the target site. Since ECT does not genetically alter the host cells and can overcome the need of
regular replacement of exhausted reservoir-type implants, disturbance to the host system can
potentially be minimized. Hydrogel materials are often applied as an encapsulating matrix
alone or as an ECT device matrix-filler to improve cell viability and avoid aggregation of diving
cells inside the semi-permeable membrane. Their permeability can be tailored to fit the meta-
bolic requirements of the encapsulated cells so as to support their prolonged survival and func-
tioning. Naturally-occurring hydrogel biomaterials such as alginate and collagen are widely
studied since they have good biocompatibility, low immunogenicity, gentle gelation mecha-
nism that can take place in the presence of cells, and are economical and readily available [6].
Collagen constitutes the greatest quantity of the total proteins in the human body, and is a
major component of the extracellular matrix (ECM). It is also one of the most extensively used
ECMmaterials in neural tissue engineering. Alginate is a linear anionic polysaccharide com-
monly purified from brown algae and is the most studied biomaterial for ECT. As alginate is
biologically inert, some studies have functionalized it with ECM or ECM-mimicking compo-
nents to improve cell survival rate through enhancing cell-material adhesion and interactions
[7–10]. ECT matrix composed of a collagen-alginate (CAC) interpenetrating network (IPN)
integrates the physical and biological strength of its constitutional biomaterials. IPN is formed
when at least one polymer is cross-linked within the immediate presence of the other, without
any covalent bonds between them and cannot be separated unless chemical bonds are broken.
CAC hydrogel demonstrated better mechanical properties in vitro when compared with algi-
nate or collagen scaffolds alone [11–13]. However, parameters essential for tuning the proper-
ties of CAC-based ECT systems as well as their drug delivery performance in vivo are not
well-understood.
GDNF is a member of the TGF-β superfamily and is a potent neuroprotective agent that
acts on neuronal cells in both central nervous system (CNS) and peripheral nervous systems at
different stages of development [14–16]. GDNF has also been applied in preclinical and clinical
trials to treat CNS degeneration and has attracted attention in ameliorating retina degenera-
tions [17–20]. GDNF has shown to promote photoreceptor and ganglion cell survival when
applied in vitro and in a range of animal models [20]. However, as GDNF has a relatively short
half-life [21], sustained delivery is warranted to overcome the need for repeated intravitreal
injections. Some delivery systems investigated for prolonged GDNF delivery include polymer-
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release systems [22–25], cellular/cell replacement therapy [26–28], and viral or non-viral-
mediated gene therapy [29–34]. No attempt has been made to date to deliver GDNF via ECT
for ocular applications to our knowledge.
Previously, we have reported a 3D collagen microencapsulation culture system that sup-
ported the growth of GDNF-secreting HEK293 cells, enhanced their protein secretion rate, and
achieved sustained GDNF secretion for up to 30 days in vitro [35]. Inclusion of alginate in the
collagen scaffold improved its cell immobilization power, supported cell growth, and controlled
the pattern of GDNF secretion [9]. In this study, the CAC ECT platform was further developed
into an intravitreally injectable gel for treating posterior eye disorders in a well-studied animal
model of recessive retinal pigmentosa (RP), the dystrophic Royal College of Surgeons (RCS)
rat. These rats have a mutation in the tyrosine kinaseMertk gene that is mainly expressed in
retinal pigment epithelial (RPE) cells, which prevents them from phagocytizing shed photore-
ceptor outer segment (OS) debris accumulated in the subretinal space, leading to photoreceptor
cell loss [36–39]. In this study, the factors impacting encapsulated cell growth, including algi-
nate concentration and initial cell density, were firstly investigated. Potentials of sustained
GDNF delivery via a CAC ECT platform was explored in vitro and in vivo. Also, the bioactivity
and therapeutic efficacy of GDNF delivered from the gel were evaluated in dystrophic RCS
rats.
Materials and Methods
Ethics Statement
All animal experiments were performed in strict accordance with the requirements of the
Cap. 340 Animals (Control of Experiments) Ordinance and Regulations, and all relevant legis-
lation and Codes of Practice in Hong Kong. All the experimental and animal handling proce-
dures were approved by the Committee on the Use of Live Animals in Teaching and Research
in The University of Hong Kong (CULATR #2529–11 and #3250–14). Rats were deeply anes-
thetized with xylazine (15mg/kg body weight) and ketamine (60mg/kg body weight). All efforts
were made to minimize suffering. Topical analgesic 0.5% Alcaine (Alcon) was applied. Painful
stimuli, including pedal withdrawal reflex and tail pinch, was applied to ensure the rats were
under anesthesia before and during the operation. Breathing rate and heart rate were regularly
checked to ensure that they were of adequate depth, rate and normal character (heart rate:
300–500 bpm and respiratory rate: 70–110 bpm). Warming devices such as heat mat and warm
chamber were applied to maintain the body temperature of the rats after anesthesia. Minimal
dissection with appropriate instruments, minimal blood loss and gentle handling of tissues
were ensured during the surgery to minimize trauma. Prophylactic antibiotic ointment
(Tobrex1, Alcon) was topically applied post-operation, and the rats were kept in a warm and
humidified chamber to recover prior to transferring them back to their cages. Rats were
checked daily for eye inflammation, evidence of weight-loss and signs of stress for the first 7
days after surgery or until the experimental endpoint, whichever occurs first. 15–20% weight
loss of the rats was used as the humane endpoint in this project. If the rats experienced serious
breathing problems or major blood loss during the intravitreal injection, they would be eutha-
nized immediately by an overdose intraperitoneal injection of pentobarbital (Alfasan) at dosage
of 100-150mg/kg to avoid unnecessary suffering.
HEK293 Cell Culture
HEK293 cells over-expressing GDNF were kindly provided by Dr. P.T. Cheung, The University
of Hong Kong [40]. Briefly, a 633bp wild-type (wt) murine GDNF cDNA was cloned into an
expression plasmid vector pHM6 (Roche) encoding the GDNF short transcript. HEK293 cells
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were then transduced with this pHM6–633wtGDNF plasmid using LipofectamineTM2000
Transfection Reagent (Life Technologies Inc.) at 4μg DNA/10μl. Cells were cultured in Dulbec-
co's modified Eagle's medium-high glucose (DMEM-HG, Life Technologies), supplemented
with 10% fetal bovine serum (FBS, Thermo Fisher Scientific) and 1% penicillin/streptomycin
(Life Technologies) at 37°C with 5% CO2. G418 sulfate (Merck) at 500μg/ml was supplemented
for selection and maintenance of positive clones. Medium containing G418 was replaced every
3 days.
Preparation of Collagen-Alginate Gel
ECT gels were manufactured based on Lee et al. [9]. Briefly, HEK293 cells were trypsinized
using 0.25% Trypsin-EDTA (Gibco) and suspended in a composite solution consisting of neu-
tralized rat-tail collagen solution type I at a final concentration of 2mg/ml and aqueous sodium
alginate (Fluka, 70:30 ratio of guluronic:mannuronic acid) at a final concentration of 0.7% or
1% (w/v). In this study, the total cell number encapsulated per gel was 1x104 or 2x105 and the
total gel volume was 2 or 4μl. These gels were about 10 and 20mm in length respectively. To
manufacture cylindrical-shaped gels with uniform diameters, glass capillary molds (Sigma-
Aldrich) were used. 2 or 4μl of the CAC-cell mixture was introduced into a 0.2M CaCl2 filled
glass mold and incubated at 37°C and 5% CO2 for 1h for alginate and collagen gelation. These
gels were immersed in a 0.2M CaCl2 bath for five minutes at room temperature and washed
with 1x PBS before transferring to 6-well or 12-well culture plates (IWAKI) for further culture
and evaluations.
Cell Migration Assay
To study the cell immobilization power of ECT gels composed of different alginate concentra-
tions, cell migration assay was carried out based on [9]. Briefly, the substrata of 12-well culture
plates were coated with collagen gel at 0.5mg/ml to provide anchorage for the ECT gels and an
enticement for the outward migration of HEK293 cells. 1x104 cells were encapsulated in a 4μl
composite gel with 0.7% or 1% (w/v) alginate. The ECT gel was embedded in the center of the
semi-set collagen gel and was further incubated in 37°C for 20 minutes to allow the complete
setting of the collagen slab. Culture medium was carefully added into the wells and replenished
every 3 days. Morphology of ECT gels and encapsulated cells were studied with phase-contrast
microscopy (n = 5). Experiments were performed in triplicates.
Characterization of ECT Gel
2μl ECT gel with 1x104 cells encapsulated in a CAC matrix of 1% alginate and 2mg/ml type I
collagen was used for subsequent in vitro and in vivo characterizations. Conditioned media of
ECT gel with or without cells was collected for GDNF analysis. The accumulated GDNF during
the first week was collected at day 7 and the second week at day 14 (n = 3–5).
Morphological Examination of ECT Gel
Temporal changes in the morphology of cultured ECT gels were examined by phase-contrast
microscopy at day 7 and 14. Also, the microstructure of ECT gel at day 14 was studied by SEM
(Hitachi S4800). ECT gels were fixed with 2.5% glutaraldehyde at 4°C overnight, rinsed and
dehydrated in gradients of ethanol before critical point drying and gold sputtering for SEM
analysis.
Sustained GDNF Delivery Promoted Photoreceptor Survival
PLOS ONE | DOI:10.1371/journal.pone.0159342 July 21, 2016 4 / 16
Measurement of GDNF Secretion
The concentration of GDNF secreted from ECT gels in vitro and in vivo was evaluated by
GDNF Emax1 ImmunoAssay (Promega) at day 7 and 14 according to the manufacturer’s
instructions. In this study, antibodies against human GDNF were used as human and murine
GDNF exhibit over 90% amino acid sequence homology and are highly species cross-reactive
[41]. Briefly, 96-well flat bottom ELISA plate (Thermo-fisher) was coated with anti-GDNF
monoclonal antibody in carbonate coating buffer overnight at 4°C without shaking. Non-spe-
cific binding sites were blocked by 1X Block and Sample Buffer at room temperature for 1 hour
before sample addition. After the addition of conditioned medium or diluted vitreous samples
and serially diluted GDNF standard (0-1000pg/ml), the plate was incubated with shaking at
150rpm for 6 hours at room temperature (EDHSHO-1D, Wise). Then the plate was incubated
with anti-human GDNF polyclonal antibody overnight at 4°C. Anti-Chicken IgY, horseradish
peroxidase conjugate was added to the plate and incubated with shaking at room temperature
for 2 hours. TMB One solution was added and the plate was incubated for 15 minutes without
shaking at room temperature. Reaction was stopped upon the addition of 1N hydrochloric
acid. Absorbance at 450nm was measured within 30 minutes with a multiplate reader (Elx800,
BioTek). TBST wash buffer was applied in the washing steps.
The accumulative GDNF secretion from ECT gel with cells or without cells in vitro was
compared at day 7 and 14. Conditioned medium were collected twice per week and were cen-
trifuged at 5000rpm for 10 minutes (5424 centrifuge, eppendorf) to remove particulates and
aliquoted for storage in -80°C before ELISA quantification. As for in vivo comparison, vitreous
was extracted from healthy Sprague Dawley (SD) rats receiving injections of ECT gel with or
without cells at post-natal day 28 (p28). These animals were sacrificed after 7 and 14 days of
implantation.
Cell Viability of ECT Gel
In order to evaluate the cell viability and morphology of implanted ECT gels, ECT gel
explanted at day 7 was incubated with 2μMCalcein AM and 4μM Ethidium homodimer-1
(Molecular Probes) for 40 minutes at room temperature for the simultaneous staining of live
and dead cells in Live/Dead assay. Results were evaluated by phase contrast and fluorescence
microscopy.
Animal Work
Animal models and surgical procedures. For in vivo studies involving the quantification
of GDNF secreted, healthy male SD rats (Laboratory Animal Unit of The University of Hong
Kong) were employed. As for evaluating the bioactivity of GDNF secreted from the implanted
ECT gel, a well-established rat model with inherited photoreceptor degeneration, the pink-
eyed dystrophic RCS/lav, was used. RCS/lav rats were obtained from Dr. Matthew LaVail
(UCSF, UCSF School of Medicine) and were bred in the Laboratory Animal Unit of The Uni-
versity of Hong Kong (LAU). Male RCS/lav rats were used in this study. All rats were kept in a
temperature-controlled room with 12-hour light/12-hour dark cycle and allowed free access to
food and water. Operation was carried out at p28 for both types of rats.
Rats were anesthetized by intraperitoneal injection of a mixture of 15mg/kg xylazine and
60mg/kg ketamine (Alfasan lab). Analgesic topical 0.5% Alcaine (Alcon) was applied pre- and
during operation. Under anesthesia, the pupil was dilated with topical 1% Mydriacyl (Alcon).
The ocular surface and surrounding tissue were sterilized with diluted Betadine solution (Mun-
dipharma A.G.), followed by cleansing with saline using a clean cotton swab. A 30G needle was
used to introduce 2 holes in the cornea for the release of intraocular pressure during intravitreal
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injection. To visualize the intraocular space and retina during surgery, a circular piece of glass
cover slip (10mm in diameter) was gently placed on the cornea with the support of a C-shaped
corneal ring between the eye and glass slip. Saline was used to fill the space in between the glass
slip, C-ring and the eye surface to allow better stability and adhesion of the slip on the corneal
surface. After introducing a small incision on the conjunctiva at the superior temporal limbal
region with a pair of conjunctival scissors to expose the sclera, an incision into the vitreous was
made using a 20-gauge blade (Alcon) without disturbing the posterior capsule, lens and retina.
ECT gel was injected into the posterior vitreous through a sterilized pipette tip with a fine
opening (Sigma-Aldrich). The wound and conjunctiva were subsequently closed with 10–0
nylon suture. Topical antibiotic TOBREX1 (Alcon Laboratories Inc.) was applied to the eye
for 2–3 days after the operation. At designated time points, rats were sacrificed by intraperito-
neal injection of pentobarbital for vitreous GDNF concentration determination and retinal
morphological examination.
In vivo GDNF delivery. Nine rats were randomly divided into 2 groups: (1) ECT with
1x104 cells/gel, and (2) ECT without cells (Fig 1). After 14 days of implantation, the animals
were sacrificed for GDNF analysis. Vitreous was collected from the enucleated eyecups and fil-
tered by centrifuging at 16000rpm for 15 minutes at 4°C (5415R centrifuge, Eppendorf) using
an ultracentrifugation unit (Millipore). Samples were stored in -80°C before ELISA quantifica-
tion. The cell-encapsulating ECT gel was collected at day 7 for morphological study and Live/
Dead assay.
Bioactivity of GDNF delivered by ECT gel. As a pilot study to investigate the stability
and therapeutic efficacy of ECT gels, two RCS/lav rats were implanted with gel containing
1x104 cells. Retinal morphology at post-operation day 28 was compared with non-operated
dystrophic rats. In a formal in vivo study to investigate the efficacy of the cell-containing ECT
gel, 26 dystrophic rats were randomly divided into four treatment groups: 1) ECT with 2x105
cells/gel (n = 9), 2) ECT without cells (n = 8), 3) surgical sham control (n = 3), and 4) unoper-
ated group (n = 6). After 28 days of implantation, the animals were sacrificed for retinal mor-
phological examination.
Retinal morphological examination. To allow effective penetration of fixative without
damaging the retinal structure, eyecups were immediately fixed in 4% paraformaldehyde
(PFA) in PBS for 1 hour after removing the cornea. After removing the lens, the eyecup was
further immersed in PFA with regular agitation at room temperature overnight before paraffin
embedding. Sagittal sections of 5μm parallel to the optic nerve were collected using a
Fig 1. Morphology of CAC ECT gel (A) without cell encapsulation and (B) with cell encapsulation (red
dotted line) inside rat eyes under a surgical microscope. The gel with no encapsulated cells was
transparent and therefore could barely be seen. Photos were taken 1 week post-operation.
doi:10.1371/journal.pone.0159342.g001
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microtome (HM 315 Microtome, Microm). Hematoxylin and eosin (H&E)-stained retinal sec-
tions were examined and imaged with an upright microscope (Eclipse 80i, Nikon, Japan). The
whole retina was imaged with about 15 microscopic fields at 400x magnification. These images
were merged with Adobe1 Photoshop1. Six regions of 810 pixels x 810 pixels were selected
along the retina for ONL cell counting. They were: 1) superior peripheral, 2) superior mid-cen-
tral, 3) superior central, 4) inferior central, 5) inferior mid-central, and 6) inferior peripheral.
ONL cell count was quantified to evaluate the degree of the photoreceptor survival. The counts
were normalized against their respective retinal length in the selection.
Statistical Analysis
All data were expressed as mean ± SD. A blinded approach was used in all the experimental
procedures. Verification of normality and homogeneity of variances were conducted before
using parametric analysis. Non-parametric two-way ANOVA Friedman’s test was used to
investigate the difference in accumulative GDNF concentration between ECT with cells and
without cells over culture time. Mann-Whitney U test was used to compare the difference in
accumulative GDNF concentration in vitreous between the treatment groups, ECT with cells
and without cells. General linear model with repeated measures and appropriate post-hoc tests
were applied to investigate the difference in ONL count among different treatments received
and retinal locations. All statistical analyses were performed using SPSS 16.0. The significance
level was set at 0.05.
Results
Alginate Concentration and Cell Immobilization
To study the effect of alginate concentration on the cell immobilization properties of ECT gels,
1x104 modified HEK293 cells with GDNF-expression were encapsulated in a 4μl CAC ECT gel
with 0.7% (Fig 2A–2C) or 1% (Fig 2D–2F) alginate for cell migration assay over 28 days of cul-
ture. Cell distribution in both types of ECT gels was similar on the day of manufacturing (day
0) (Fig 2A and 2D). The distribution remained very similar over 28 days of culture for the 1%
Fig 2. Temporal changes in cell immobilization at different alginate concentrations evaluated by cell
migration assay. 1x104 cell were encapsulated in a CACmatrix of (A-C) 0.7% or (D-E) 1% alginate and
examined at day 0 (day of manufacturing), 7 and 28 (left to right). (A, D) The initial cell distribution was similar.
(B) At day 7, cell colonies formation and mild migration of cells were observed in 0.7% alginate gels. (C) At
day 28, colonies further expanded in size. Colonies located close to the outer regions of the gel or ones that
had expanded to that region showed higher chances of cell migration from the gel to the surrounding (*, #).
(D-F) Cell distribution in 1% alginate gel remained similar at day 0, 7 and 28. Scale Bar = 200μm.
doi:10.1371/journal.pone.0159342.g002
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alginate group (Fig 2D–2F). As for the 0.7% group, cell colonies formation and mild migration
of cells were observed at day 7. At day 28, these colonies further expanded in size. Colonies
located close to the outer regions of the gel (Fig 2B and 2C) or ones that has expanded to that
region showed higher chances of cell migration from the gel to the surrounding (Fig 2C). Also,
colonies at the center regions of the gel fused together at day 28. 1% alginate was more effective
in immobilizing cells than 0.7% alginate over 28 days of culture at this cell density.
Characterization of ECT Gel
Doubled cell density by halving the total gel volume appeared to support better cell morphol-
ogy at day 7 and 14 compared with lower cell density over 2 weeks of culture (Figs 3A, 3B and
1E). SEM imaging of the gel at day 14 showed entrapped cells within a meshwork-like CAC
matrix (Fig 3E–3H). The CAC matrix was arranged in an IPN of alginate (Fig 3G) and recon-
stituted collagen (Fig 3H).
As a pilot study to investigate cell viability and gel morphology of the implanted ECT gel,
the gel was retrieved from rat vitreous after 7 days of implantation (Fig 3C and 3D). The gross
gel morphology and cell distribution after 7 days of implantation were similar to that of the
pre-implanted gels., An increase in cell colony size was observed in both cultured and
explanted gels at day 7 when compared to day 0. The colony size and density of the cells in the
cultured gel (Fig 3A) appeared to be greater than that of the explanted gel (Fig 3C). Good cell
viability was observed throughout the explanted gel with plenty of live cells and a very low
amount of dead cells (Fig 3D).
In Vitro and In VivoGDNF Secretion
Compared with the control ECT gel without cells, continuous GDNF delivery from the cell-
encapsulating gel was detected in culture (Fig 4A) and rat vitreous for at least 14 days by
GDNF ELISA. For in vitro accumulated GDNF level, non-parametric Friedman’s test showed a
significant difference between the treatment groups (p<0.042). A slight decrease in the accu-
mulated GDNF concentration was also detected in the second week compared to the first
week. As for accumulated in vivo GDNF level, Mann-Whitney U test indicated a significant
difference between the cell-encapsulating gel (1628.53±204.56 pg/ml) and the gel without cells
(25.24±0.92 pg/ml) by day 14 (p = 0.016).
Bioactivity of GDNF Delivered from ECT Gel
In a pilot study using ECT gel with a lower cell density, rats implanted with gel containing
1x104 cells showed a better photoreceptor nuclei retention in the ONL than non-operated rats
after 28 days of implantation at p56 (Fig 4B). For the peripheral retinal region (about 150μm
from the peripheral end of retina), the ONL density of ECT-implanted rats and non-treated
rats were 538±46 and 278±73 cells/mm respectively. Also, ONL in the treated rats was thicker
than that in the non-treated rats. As for the central retinal region (about 150μm away from the
optic nerve), ONL density of the ECT-implanted rats and non-treated rats were 271±36 and
128±34 cells/mm respectively.
In a formal study on the efficacy of cell-containing ECT gels, rats implanted with gels con-
taining 2x105 cells (Fig 5A-d and 5A-h) showed more photoreceptors over all retinal regions of
examination (Fig 5B) than other control groups, including ECT without cells (Fig 5A–c and
5A-g), surgical sham control (Fig 5A-b and 5A-f), and non-operated control (Fig 5A–a and
5A-e). H&E-staining revealed better ONL alignment and thickness in the rats receiving cell-
encapsulating gel. General linear model with repeated measures showed that ONL count at p56
was significantly affected by both treatment received (p<0.0005) and retinal location
Sustained GDNF Delivery Promoted Photoreceptor Survival
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(p<0.0005) (Fig 5C). For treatment received, Bonferroni post-hoc test showed that the ONL
count in the ECT with cells group was significantly higher than the other treatment groups,
including ECT without cells (p = 0.006), sham (p<0.0005) and non-operated groups
(p<0.0005). In which, the ONL count in the ECT with cells group was at least one-fold higher
Fig 3. Characterizations of 2μl CAC ECT gel with 1x104 cells using (A-C) phase contrast imaging, (D) Live/
Dead assay, and (E-H) SEM.Morphology of ECT gel at (A) day 7 and (B) day 14 in vitro, and (C) explanted gel at
post-implantation day 7 were evaluated by phase contrast microscopy. (D) Cell viability in the explanted gel was
further studied by dual fluorescence staining of live (green) and dead (red) cells. Scale bar = 500μm.
Microstructure of in vitro ECT gel at day 14 was examined by SEM: (E) gross appearance of the gel (1.4K x); (F)
magnified view of the cross-section of the gel with cells entrapped in the composite gel matrix (2.2K x); (G)
magnified view of the composite matrix with an IPN of collagen and alginate (25K x); and (H) magnified view of the
hydrogel matrix showing a reconstituted collagen network (25K x). Since the ECT gel has a 3D structure, imaging
under the samemagnification may still result in varying apparent magnifications due to the difference in sample
depth. For example, (H) was shallower than (G).
doi:10.1371/journal.pone.0159342.g003
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than the sham and non-operated groups over all six areas of examination. As for retinal loca-
tion, Bonferroni post-hoc test showed that the ONL count in central retinal regions was signifi-
cantly lower than peripheral regions. The superior central has a significantly lower count than
the superior peripheral (p = 0.002), and the inferior central was significantly lower than the
inferior peripheral (p = 0.019). Additionally, cross comparisons between the central and
peripheral regions of the superior and inferior retina showed similar results. The superior cen-
tral ONL count was lower than the inferior peripheral (p = 0.04), whereas the inferior central
has a lower count than the superior peripheral (p<0.0005).
Discussion
We have previously reported that the incorporation of alginate in 3D collagen cultures of
GDNF-secreting HEK293 in: (1) a composite CAC matrix form, or (2) a two-phase form with
collagen ECT microspheres embedded in alginate, improved cell immobilization properties of
the collagen ECT scaffolds, supported cell growth, and controlled the pattern of GDNF secre-
tion [9]. In this study, the composite CAC ECT system was further developed into an injectable
gel for sustained drug delivery in the posterior eye. In this study, the ECT gels were fabricated
under physiologically relevant conditions, which involved mild temperature and ionic concen-
trations to initiate sol-gel formation, to allow simultaneous encapsulation of living cells. SEM
revealed that the CAC matrix formed under the current protocol was arranged in an IPN with
cells entrapped within a randomly arranged alginate and collagen matrix.
The survival and proliferation of mammalian cells are tightly regulated by their microenvi-
ronment through cell-extracellular matrix interactions and cell-cell adhesion. In a CAC system,
alginate polymers presents no intrinsic cell-binding domains and minimal protein adsorption
while type I collagen has peptide motifs for direct and indirect cell-binding. With minimal
Fig 4. Concentration and bioactivity of GDNF delivered from the CAC ECT gel. (A) Box plot showing the accumulated concentration of GDNF secreted
from the CAC ECT gel during the first and second week of culture. The ECT gel with cells showed a significantly higher GDNF release than the control group
(p<0.045). (B) Photoreceptor survival after the implantation of ECT gel with 1x104 cells (right) was compared to that of the non-treated control (left) at the
central (top) and peripheral retinal regions (bottom). Better cell and spatial pattern retention in the ONL were detected after treatment with cell-containing
ECT gel. Scale bar = 50μm.
doi:10.1371/journal.pone.0159342.g004
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interaction in alginate, cells encapsulated in the 3D CAC matrix showed a reduced cell growth
when compared to unconstrained growth in monolayer culture. Comparing with alginate gels
of higher concentrations, i.e. 2 and 4%, Lee et al. reported better cell viability, and more impor-
tantly, much higher GDNF secretion rate in 1% gels [9]. Based on these findings, optimization
of alginate concentrations at the lower end was carried out in this study. To determine the
effectiveness of<1% alginate gels in cell immobilization, cell migration assay at 0.7% was also
performed. The cell migration assay demonstrated that a higher alginate concentration was
necessary for better cell proliferation control and prevention of cell leakage from the ECT gel.
Similar to previous reports on proliferative cells encapsulated in CAC or alginate matrix, lower
Fig 5. Photoreceptor survival in dystrophic RCS/lav rats evaluated by H&E staining. (A, B) Six retinal
areas studied were: peripheral, mid-central and central regions of the (a-d) superior and (e-h) inferior retina
respectively. (A) H&E staining at p56 showing the retinal morphology of rats receiving: (a, e) no operation, (b,
f) surgical sham operation, (c, g) ECT gel without cells, and (d, h) ECT gel with 2x105 cells for 28 days. The
ECT with cells group showed better-aligned and thicker ONL than the other control groups. Preservation of
photoreceptors at the periphery was better than that of the central areas in all treatment groups. Straight red
line denoted the inner boundary of the ONL, adjacent to the inner nuclear layer (INL). Dashed red line
represented the outer boundary of the ONL, adjacent to the RPE. Transiting from the peripheral to central
retinal regions, ONL cells becamemore dispersed and the outer ONL boundary became unclear, especially
in the (b, f) sham and (g) ECT without cells groups. Scale bar = 25μm. (C) ONL count was significantly
affected by both treatments received (p<0.0005) and retinal location (p<0.0005). Among the treatments
received, ONL count in the ECT with cell group was significantly higher than the other treatment groups,
namely ECT without cells (p = 0.006), sham (p<0.0005) and non-operated group (p<0.0005). As for the retinal
location, ONL count in the peripheral retina was higher than the central retina.
doi:10.1371/journal.pone.0159342.g005
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alginate concentration was associated with higher initial viability but faster spheroid formation
in the ECT gel [9, 42]. Since cell leakage was already observable at day 7 for the 0.7% gel, this
group was determined to be unfit for prolonged in vivo drug delivery applications. Hence, fur-
ther quantification on its cell viability was not performed.
An increase in initial cell density showed better cell growth at 14 days of culture with cell
colonies gradually increasing in size. When cells were encapsulated in a CAC or collagen
matrix, they adhered and pulled on the collagen molecules, leading to the remodulation of
their microenvironment. Such force was generated from cytoskeletal assembly and cell move-
ments initiated by the formation of stable integrin-mediated attachments between collagen and
cells. Depending on the concentration and degree of cross-linking of collagen in the CAC com-
posite matrix, cells faced different levels of resistance to deform the matrix [43]. Higher density
of cells might create a stronger pull for a tighter arrangement of collagen around them, and
hence, through improving the cell-cell and cell-matrix interactions, cell growth and prolifera-
tion could be enhanced. Slower cell proliferation was previously reported when 3T3 fibroblasts
were encapsulated in alginate gel at low seeding density when compared to intermediate den-
sity [42].
Continuous GNDF delivery from the ECT gel was detected in culture and in the eyes of
healthy SD rats for at least 14 days. The gel was well-tolerated and no host tissue was detected
on its surface. Also, there were no observable side effects or complications in rats due to CAC
ECT implantation. No animals were rejected from this study based on the aforementioned
humane endpoint criteria. GDNF was released at around 70 pg/ml/day in culture conditions.
Due to a smaller distribution volume in SD rat eye, higher GDNF concentrations of 1.6 ng/ml
were detected in vivo by day 14. It was higher than the normal amount of GDNF present in
native SD rat retinal tissue, which was around 6.1 pg per μg total retinal protein [44]. After nor-
malization with rat vitreous volume, GDNF secretion rate was around 140 pg/day. To gain a
better understanding of the gel viability and morphology after implantation, the ECT gel was
retrieved at day 7 for Live/Dead analysis. The explanted gel showed healthy cell colonies with a
similar distribution as the pre-implanted gel. Colonies in the explanted gel were smaller in size
compared with that of the cultured gel at day 7. Slower cell growth may be attributable to the
more stringent ocular environment for the survival of transplanted cells when compared to in
vitro cultures. The difference in oxygen and nutrient availability in the eye may also affect the
rate of drug delivery. Clinical trials with the neurotrophic factor releasing ECT system,
Renexus1 (Neurotech), implanted in patients with retinal degeneration reported positive
safety profile and ability to produce sustainable drug levels [45]. In a pharmacokinetic analysis
on Renexus1, vitreous drug concentration of “high dose” implant was found to remain rela-
tively stable at around 46-54pg/day. However, the in vivo secretion rate was about 10–15 folds
lower than that from explants (600-2800pg/day). A similar fold difference was observed in a
rabbit model [46]. Further studies on pharmacokinetics and cell viability in the explanted ECT
gels after longer periods of implantation were warranted for the better understanding in the
performance and stability of CAC-based platforms in vivo. Although the GDNF concentration
in rat eyes has declined, it should not impact the drug delivery application significantly as pho-
toreceptor survival was detectable in dystrophic rats after 28 days of ECT gel implantation.
Since the majority of CAC gel characterization was performed at day 14 in our previous study
[9], this time point was chosen to evaluate our initial design with 1x104 cells. Based on our
pilot data, where ECT with 1x104 cells resulted in limited ONL cell retention effect, higher cell
concentration of 2x105 was applied in a similar design to test for neuroprotective effects in the
subsequent formal morphological rescue study.
To evaluate the bioactivity of GDNF delivered, ECT gel was implanted in dystrophic RCS
rats at p28. Rats receiving ECT with cells showed better ONL retention than control rats
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receiving ECT without cells, sham or no treatment. Retina morphological studies showed a
similar degeneration pattern across all treatment groups. ONL cell loss in the central retinal
was more severe than the peripheral regions. In the pilot study with ECT containing 1x104
cells, ONL nuclei density and thickness of the treated rats were about 1 fold higher than the
non-treated rats at the peripheral retinal region. As for the central retinal region, where photo-
receptor degeneration was most severe, although the apparent ONL thickness was similar in
both treatment groups, ONL nuclei density of the ECT-implanted rats was about one fold
higher than that of the non-operated rats. Also, the spatial arrangement of ONL nuclei in the
treated rats was better than that of the control group. The rats implanted with gel containing a
higher initial cell number (2x105) appeared to show better photoreceptor survival in yielding
better ONL organization and higher ONL count (733±134 vs. 538±46 cells/mm retina with
1x104 cells/gel at peripheral retina, and 415±153 vs. 271±36 cells/mm retina with 1x104 cells/
gel at central retina). When compared with the sham and non-operated controls, ONL count
in the rats receiving ECT with 2x105 cells/gel was at least one fold higher across the retina.
Also, although no significant alterations were observed in the retinal morphology, more inves-
tigations would be needed to evaluate the temporal changes in retinal response to the gel on
cellular and molecular levels. Such an absence in acute response may be contributed by the
immunoprivileged status of the eye.
As the gelation process of Ca2+ and alginate is inherently reversible, Ca-alginate scaffolds
may slowly dissociate through the gradual exchange of gelling divalent Ca2+ ions with sodium
ions, or in the presence of calcium chelators or non-gelling cations upon long-term intravitreal
implantation. Alginate hydrogel stability and long-term encapsulation power can be improved
by forming stable cross-links with bifunctional crosslinkers or polymers such as poly-l-lysine,
poly-l-ornithine, chitosan, and poly (ethylene glycol) [47–52].
Conclusions
In order to circumvent repeated invasive intravitreal injections and improve drug availability at
the neural retina, an implantable ECT gel with a composite collagen-alginate hydrogel matrix was
developed to provide continuous GDNF delivery in the vitreous for treating posterior eye dis-
eases. Alginate concentration and initial cell density were important factors to be considered
when optimizing ECT systems with proliferative cells. Gels with lower alginate concentration
yielded higher initial cell viability but faster spheroid formation while increasing initial cell density
encouraged cell growth. The gel was able to support and control cell growth, and achieved sus-
tainable GDNF delivery for up to 14 days in vitro and in vivo. Also, gels implanted in dystrophic
Royal College of Surgeons rat eyes for 28 days retained photoreceptors while those containing
higher initial cell number yielded better photoreceptor survival. In summary, the current ECT gel
has shown to be a feasible solution to delivery GNDF into the vitreous for treating degenerative
retinopathies. This study contributes towards the development of CAC hydrogel-based ECT
implants for sustained-release of future therapeutics for treating posterior eye diseases.
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